Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 8/20 | 0.40 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071024 | 0.82 | HPGD (0.50) | POLBSMN1; SMN2HTT | |
| SCHEMBL6071298 | 0.81 | HDAC1 (0.47) | POLBMETTL3KDRHDAC2HDAC6 | |
| SCHEMBL6070184 | 0.81 | NPC1 (0.38) | POLBMETTL3KDR | |
| SCHEMBL6071299 | 0.80 | ROCK2 (0.49) | MAPK1 | |
| SCHEMBL6070823 | 0.79 | HDAC3 (0.42) | MAPK1SMN1; SMN2METTL3KDR | |
| SCHEMBL6070912 | 0.79 | MAPK1 (0.51) | MAPK1 | |
| SCHEMBL6071459 | 0.78 | RAD52 (0.44) | POLBHTT | |
| SCHEMBL6071333 | 0.77 | NHERF1 (0.41) | SMN1; SMN2FLT1KDR | |
| SCHEMBL6071049 | 0.76 | HDAC3 (0.38) | METTL3KDR | |
| SCHEMBL6071129 | 0.74 | SMYD2 (0.55) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | claimed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MAPK1 127/4885POLB 1184/4885SMN1; SMN2 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.